Between 2010 and 2012 Gary Rabin, then CEO of the stem cell player Advanced Cell Technology, sold $1.5 million worth of his shares in 27 transactions. But according to the SEC, Rabin never told investors of his stock sales--a strict no-no that is now costing the ex-CEO a $175,000 penalty, with the Marlborough, MA-based biotech company agreeing to fork over $375,000 as it reviews its compliance policy.
The new nod could boost sales of the French drugmaker's vaccine, a lift it could use after Menactra's top-line haul in 2013 sank to €424 million in a 21.5% slide.
Sanofi's dengue vaccine isn't slated to hit the market until late next year, pending approval, but it already has some competition on the horizon. Takeda has its eye on nods in the U.S. and Europe for its own candidate by the 2017-18 fiscal year, it says.
For nearly two years, the FDA and a Texas compounder have been sparring over whether its products are safe and whether it will bend to the pressure the agency is exerting. The FDA sent a warning on Tuesday saying that the company cannot affirm its products are safe and that providers were taking a chance by using them.
More than three long years after Orexigen was turned back at the FDA and forced to do a costly late-stage safety study of its weight drug Contrave, the agency has come back and given its seal of marketing approval to the drug.
Amid growing action from U.S. lawmakers to curb corporate inversions, top Senate Democrats revealed a plan to rein in the deals that would allow med tech companies to shift their domiciles abroad for tax-paying purposes.
Alan Mertz, president of the American Clinical Laboratory Association, ripped into the FDA's proposal to regulate lab-developed tests yesterday in testimony to Congress during a hearing of the 21st Century Cures initative.
NPS Pharma is moving toward FDA approval with its treatment for a rare disease, as agency staff applauded the drug's efficacy ahead of a make-or-break panel vote.
Pharma companies devote a lot of resources to winning over the U.K.'s drug price watchdog, the National Institute for Health and Care Excellence (NICE). Now, NICE says it will start looking beyond pharma companies for data, to get a more complete picture of whether new drugs are really worth their high costs.
A group of FDA advisers voted against recommending approval for a new combination blood-pressure treatment from Actavis, clouding the future of a prospect the company picked up in its $28 billion buyout of Forest Laboratories.